158 related articles for article (PubMed ID: 9106629)
41. The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes.
Bour S; Iglesias-Osma MC; Marti L; Duro P; Garcia-Barrado MJ; Pastor MF; Prévot D; Visentin V; Valet P; Moratinos J; Carpéné C
Eur J Pharmacol; 2006 Dec; 552(1-3):20-30. PubMed ID: 17056035
[TBL] [Abstract][Full Text] [Related]
42. I2-Imidazoline receptors and monoamine oxidase B enzyme sites in human brain: covariation with age.
Ballesteros J; Maeztu AI; Callado LF; Gutiérrez M; García-Sevilla JA; Meana JJ
Neurosci Lett; 2000 Jul; 288(2):135-8. PubMed ID: 10876079
[TBL] [Abstract][Full Text] [Related]
43. Presynaptic imidazoline receptors and non-adrenoceptor [3H]-idazoxan binding sites in human cardiovascular tissues.
Molderings GJ; Likungu J; Jakschik J; Göthert M
Br J Pharmacol; 1997 Sep; 122(1):43-50. PubMed ID: 9298527
[TBL] [Abstract][Full Text] [Related]
44. Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine.
MacInnes N; Handley SL
Br J Pharmacol; 2002 Mar; 135(5):1227-34. PubMed ID: 11877331
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological and molecular discrimination of brain I2-imidazoline receptor subtypes.
Olmos G; Alemany R; García-Sevilla JA
Naunyn Schmiedebergs Arch Pharmacol; 1996 Dec; 354(6):709-16. PubMed ID: 8971730
[TBL] [Abstract][Full Text] [Related]
46. Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework.
Shetnev A; Osipyan A; Baykov S; Sapegin A; Chirkova Z; Korsakov M; Petzer A; Engelbrecht I; Petzer JP
Bioorg Med Chem Lett; 2019 Jan; 29(1):40-46. PubMed ID: 30455149
[TBL] [Abstract][Full Text] [Related]
47. Pharmacologic and molecular discrimination of I2-imidazoline receptor subtypes.
Olmos G; Alemany R; Boronat MA; García-Sevilla JA
Ann N Y Acad Sci; 1999 Jun; 881():144-60. PubMed ID: 10415910
[TBL] [Abstract][Full Text] [Related]
48. Type A and B monoamine oxidase activities in the human and rat kidney.
Fernandes MH; Soares-da-Silva P
Acta Physiol Scand; 1992 Aug; 145(4):363-7. PubMed ID: 1529723
[TBL] [Abstract][Full Text] [Related]
49. Pharmacological modulation of immunoreactive imidazoline receptor proteins in rat brain: relationship with non-adrenoceptor [3H]-idazoxan binding sites.
Escribá PV; Alemany R; Sastre M; Olmos G; Ozaita A; García-Sevilla JA
Br J Pharmacol; 1996 Aug; 118(8):2029-36. PubMed ID: 8864539
[TBL] [Abstract][Full Text] [Related]
50. Interactions of imidazoline ligands with the active site of purified monoamine oxidase A.
Jones TZ; Giurato L; Guccione S; Ramsay RR
FEBS J; 2007 Mar; 274(6):1567-75. PubMed ID: 17480205
[TBL] [Abstract][Full Text] [Related]
51. Computational comparison of imidazoline association with the I2 binding site in human monoamine oxidases.
Basile L; Pappalardo M; Guccione S; Milardi D; Ramsay RR
J Chem Inf Model; 2014 Apr; 54(4):1200-7. PubMed ID: 24601544
[TBL] [Abstract][Full Text] [Related]
52. Autoradiographic localisation of [3H]2-BFI imidazoline I2 binding sites in mouse brain.
MacInnes N; Handley SL
Eur J Pharmacol; 2005 Jun; 516(2):139-44. PubMed ID: 15925361
[TBL] [Abstract][Full Text] [Related]
53. Imidazoline-guanidinium receptive site in renal proximal tubule: asymmetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance.
Coupry I; Atlas D; Podevin RA; Uzielli I; Parini A
J Pharmacol Exp Ther; 1990 Jan; 252(1):293-9. PubMed ID: 2153803
[TBL] [Abstract][Full Text] [Related]
54. Molecular aspects of monoamine oxidase B.
Ramsay RR
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():81-9. PubMed ID: 26891670
[TBL] [Abstract][Full Text] [Related]
55. Imidazoline I(2)-receptors and spinal reflexes in the decerebrated rabbit.
Clarke RW; Harris J; Ogilvie J
Neuropharmacology; 2000 Jul; 39(10):1904-12. PubMed ID: 10884571
[TBL] [Abstract][Full Text] [Related]
56. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain.
Olmos G; Gabilondo AM; Miralles A; Escriba PV; García-Sevilla JA
Br J Pharmacol; 1993 Mar; 108(3):597-603. PubMed ID: 8385528
[TBL] [Abstract][Full Text] [Related]
57. Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands.
Holt A; Wieland B; Baker GB
Br J Pharmacol; 2004 Oct; 143(4):495-507. PubMed ID: 15451775
[TBL] [Abstract][Full Text] [Related]
58. Association between I(2) binding sites and monoamine oxidase-B activity in platelets.
Zhu H; Piletz JE
Ann N Y Acad Sci; 2003 Dec; 1009():347-52. PubMed ID: 15028609
[TBL] [Abstract][Full Text] [Related]
59. Imidazoline binding domains on MAO-B. Localization and accessibility.
Raddatz R; Savic SL; Lanier SM
Ann N Y Acad Sci; 1999 Jun; 881():26-31. PubMed ID: 10415893
[TBL] [Abstract][Full Text] [Related]
60. Dopamine induces ERK activation in renal epithelial cells through H2O2 produced by monoamine oxidase.
Vindis C; Séguélas MH; Lanier S; Parini A; Cambon C
Kidney Int; 2001 Jan; 59(1):76-86. PubMed ID: 11135060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
